Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC

BSE3130.5532.15 (+1.04 %)

PREV CLOSE ( ) 3098.40

OPEN PRICE ( ) 3109.60

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 1331

TODAY'S LOW / HIGH ( )3093.05 3157.85

52 WK LOW / HIGH ( )1924.3 3515.95

NSE3131.4032.8 (+1.06 %)

PREV CLOSE( ) 3098.60

OPEN PRICE ( ) 3121.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 3131.40 (10)

VOLUME 58819

TODAY'S LOW / HIGH( ) 3090.00 3161.00

52 WK LOW / HIGH ( )1921 3515.7

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924

Management Info

Renu Sud Karnad - Chairman Bhushan Akshikar - Managing Director

Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email askus@gsk.com / in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

20Jun GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 30 read with para A of Part A of Schedule III of..

15May GlaxoSmithKline Pharmaceuticals inform
In compliance with the provisions of Regulation 24A of SEBI LODR Amendme..

15May GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 47 of the Listing Obligations and Disclosure Requ..

15May GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 30(6) of Schedule III, of the Listing Obligations..

13May GlaxoSmithKline Pharmaceuticals inform
GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board..

Financials

Rs. in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	2601.4	9190.6
Gross Profit	3549	12484.4
Operating Profit	3702	13118.5
Net Sales	9660.8	37234.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 34745.50 (1.62%)	M.Cap ( in Cr)73831.76
Gland Pharma (BSE) 2039.40 (4.04%)	M.Cap ( in Cr)33600.42
Procter&Gamble Healt (BSE) 5920.55 (1.00%)	M.Cap ( in Cr)9827.75
Torrent Pharma (BSE) 3554.05 (1.45%)	M.Cap ( in Cr)120285.20
Onesource Specialty (BSE) 1998.40 (2.54%)	M.Cap ( in Cr)22874.89

Shareholding Pattern

	PROMOTERS	75%
	NON-INSTITUTION	12.41%
	MUTUAL FUNDS/UTI	5.17%
	FI/BANKS/INSURANCE	2.41%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Nippon India Pharma...	3.63
360 ONE Quant Fund-Reg(G)	3.13
Bajaj Finserv Healt...	2.59
Aditya Birla SL MNC...	2.48
Tata Nifty MidSmall...	2.37
Motilal Oswal Nifty...	2.36
ICICI Pru Quant Fund(G)	2.34

Risk Disclosures on Derivatives

Smart Quotes

GLAXOSMITHKLINE PHARMACEUTICALS LTD.